Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- Eidos Therapeutics, a BridgeBio company
- Study ID
- NCT04988386
- Phase
- PHASE3
- Status
- Active Not Recruiting
Conditions
- Amyloid Cardiomyopathy, Transthyretin-Related
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 90 Years
- Healthy Volunteers
- Not accepted
Interventions
- Acoramidis (AG10) — DRUGAcoramidis (AG10) twice daily
Study Details
Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)
Key Dates
- Start date
- Oct 27, 2021
- Status verified
- Oct 2025
- Primary completion
- Apr 15, 2028
- Completion
- May 15, 2028
Study Design
- Enrollment
- 389 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: AG10Open-label study all participants will receive AG10 during this study.
Primary Outcome Measure
Incidence of treatment-emergent Adverse Events [Safety and Tolerability] [ Time Frame: 60 months ]
Locations (26)
Find similar trials in Los Angeles, CA
By research site
Cedars-Sinai Medical Center· Los Angeles, CAUniversity of Colorado Hospital - Anschutz Medical Campus· Aurora, CONorthwestern University· Chicago, ILUniversity of Chicago Medical Center· Chicago, ILNorthShore University Health System· Evanston, ILMedStar Medical Group Cardiology at Franklin Square· Baltimore, MD